Journal article 488 views
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
David M Williams,
Matthew Staff,
Steve Bain 
,
Thinzar Min
,
Thinzar Min
Endocrinology, Volume: 18, Issue: 1, Start page: 43
Swansea University Authors:
Steve Bain , Thinzar Min
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.17925/ee.2022.18.1.43
Abstract
There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective the...
| Published in: | Endocrinology |
|---|---|
| ISSN: | 2752-5457 2752-5457 |
| Published: |
Touch Medical Media, Ltd.
2022
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa60990 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™ - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy. [Abstract copyright: © Touch Medical Media 2022.] |
|---|---|
| Keywords: |
obesity, liraglutide, weight management, weight loss, type 2 diabetes, semaglutide, overweight, diabetes mellitus, Glucagon-like peptide-1 (GLP-1) receptor analogue |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
1 |
| Start Page: |
43 |